New dose schedule for J&J bispecific; Layoffs at Ring Therapeutics; Regeneron’s priority review

Plus, news about En­ver­ic Bio­sciences and Kazia Ther­a­peu­tics:

John­son & John­son’s bis­pe­cif­ic gets a new dos­ing sched­ule: The FDA ap­proved a re­duced dos­ing reg­i­men for J&J’s mul­ti­ple myelo­ma bis­pe­cif­ic an­ti­body Tec­vayli, the phar­ma com­pa­ny an­nounced Tues­day evening. The re­duced dos­ing ap­proval comes as the drug’s side ef­fects, such as cy­tokine re­lease syn­drome and se­ri­ous in­fec­tions, are sub­stan­tial. The treat­ment is ap­proved for mul­ti­ple myelo­ma pa­tients who have re­ceived four pri­or lines of ther­a­py, but now those who have been in re­mis­sion for at least six months can move down from a week­ly to a bi­week­ly dos­ing sched­ule. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.